INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
Public company

IAMIambic Therapeutics, Inc.

CIK 0001997038

EDGAR filingsOpen in network
Disclosed transactions38
Buys / sells1 / 0
Max Insider Score49
Connections13with evidence

IAM · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
742.5K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Catalio Nexus Fund III, LP10% Owner · Oct 19, 2026
  • ← Insider ofevidence
    Catalio Access Fund VIII, LLC10% Owner · Oct 19, 2026
  • ← Insider ofevidence
    Catalio BH SPV, LLC10% Owner · Oct 19, 2026
9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C
—
410.8K sh
Oct 16, 2026
Oct 19, 2026
traded Oct 16, 2026
+3d
SEC FORM 4

Evidence

9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
2.00M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.46M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
57.8K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.14M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
731.2K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
122.7K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.46M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
VJ
Vogelstein R JacobDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
742.5K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.46M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

17
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
410.8K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

49
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Open-market purchase
BUY$11.50M
718.8K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.15M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
57.8K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
306.7K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
Catalio Capital Management, LP10% Owner
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
2.00M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
Catalio Capital Management, LP10% Owner
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.46M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
Catalio Capital Management, LP10% Owner
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
742.5K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
Catalio Capital Management, LP10% Owner
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.14M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
Catalio Capital Management, LP10% Owner
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
731.2K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
Catalio Capital Management, LP10% Owner
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
122.7K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
Catalio Capital Management, LP10% Owner
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
1.46M sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
Catalio Capital Management, LP10% Owner
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
742.5K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

17
SM
Secora MichaelCFO & Chief Corp Dev Ofcr
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
61.3K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

9
SM
Secora MichaelCFO & Chief Corp Dev Ofcr
IAMIambic Therapeutics, Inc.
Derivative conversion
C—
61.3K sh
Oct 16, 2026Oct 19, 2026
traded Oct 16, 2026
+3dSEC FORM 4

Evidence

13
MR
Manby Frederick RDirector, Chief Technology Officer
IAMIambic Therapeutics, Inc.
Grant or award
A—
132.2K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence

9
MR
Manby Frederick RDirector, Chief Technology Officer
IAMIambic Therapeutics, Inc.
Grant or award
A—
793.2K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence

21
OA
Olson Peter AChief Scientific Officer
IAMIambic Therapeutics, Inc.
Grant or award
A—
19.5K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence

9
OA
Olson Peter AChief Scientific Officer
IAMIambic Therapeutics, Inc.
Grant or award
A—
116.9K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence

0
VJ
Vogelstein R JacobDirector, 10% Owner
IAMIambic Therapeutics, Inc.
Grant or award · 10b5-1 plan
A—
20.3K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence

9
RL
Rachlin Evan LockwoodDirector
IAMIambic Therapeutics, Inc.
Grant or award
A—
20.3K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence

13
MF
Miller Thomas F.Director, Chief Executive Officer
IAMIambic Therapeutics, Inc.
Grant or award
A—
132.2K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence

9
MF
Miller Thomas F.Director, Chief Executive Officer
IAMIambic Therapeutics, Inc.
Grant or award
A—
793.2K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence

21
JN
Josephson NeilChief Medical Officer
IAMIambic Therapeutics, Inc.
Grant or award
A—
31.0K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence

9
JN
Josephson NeilChief Medical Officer
IAMIambic Therapeutics, Inc.
Grant or award
A—
185.9K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence

13
SM
Secora MichaelCFO & Chief Corp Dev Ofcr
IAMIambic Therapeutics, Inc.
Grant or award
A—
28.4K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence

9
SM
Secora MichaelCFO & Chief Corp Dev Ofcr
IAMIambic Therapeutics, Inc.
Grant or award
A—
170.3K sh
Oct 14, 2026Oct 16, 2026
traded Oct 14, 2026
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Petrocheilos George C10% Owner · Oct 19, 2026
  • ← Insider ofevidence
    Catalio Capital Management, LP10% Owner · Oct 19, 2026
  • ← Insider ofevidence
    Olson Peter AChief Scientific Officer · Oct 16, 2026
  • ← Insider ofevidence
    Vogelstein R JacobDirector, 10% Owner · Oct 16, 2026
  • ← Insider ofevidence
    Rachlin Evan LockwoodDirector · Oct 16, 2026
  • ← Insider ofevidence
    Miller Thomas F.Director, Chief Executive Officer · Oct 16, 2026
  • ← Insider ofevidence
    Josephson NeilChief Medical Officer · Oct 16, 2026
  • ← Insider ofevidence
    Secora MichaelCFO & Chief Corp Dev Ofcr · Oct 16, 2026
  • ← Insider ofevidence
    Manby Frederick RDirector, Chief Technology Officer · Oct 16, 2026